Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Lin, D ^b   Li, W K ^b   Rieder, Michael J ^a  

^a CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

^b NONE

Author keywords

AIDS related opportunistic infections *drug therapy ; Anti infective agents adverse effects; *therapeutic use ; Desensitization, immunologic; Drug hypersensitivity etiology; immunology ; Randomized controlled trials as topic

Indexed keywords

COTRIMOXAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC PROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DESENSITIZATION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPPORTUNISTIC INFECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 44949150177     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005646.pub2     Document Type: Review

References (46)

1. Bonfanti 2000 {published data only} Bonfanti P, Pusterla L, Parazzini F, Libanore M, Cagni AE, Franzetti M, Faggion I, Landonio S, Quirino T. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. Biomedicine & pharmacotherapy 2000;54:45-9.
2. Leoung 2001 {published data only} Leoung GS, Stanford JF, Giordano MF, Stein A, Torres RA, Giffen CA, Wesley M, Sarracco T, Cooper EC, Dratter V, Smith JJ, Frost KR. Trimethoprim-Sulfamethoxazole (TMP-SMZ) Dose Escalation versus Direct Rechallenge for Pneumocystis Carinii Pneumonia Prophylaxis in Human Immunodeficiency Virus-Infected Patients with Previous Adverse Reaction to TMP-SMZ. The Journal of Infectious Diseases 2001;184:992-7.
3. Straatmann 2002 {published data only} Straatmann, A, Bahia F, Pedral-Sampaio D, Brites C. A Randomized, Pilot Trial Comparing Full Versus Escalating Dose Regimens for the Desensitization of AIDS Patients Allergic to Sulfonamides. The Brazilian Journal of Infectious Disease 2002;6:276-280.
4. Picketty 1995 Picketty C, Gilquin J, Kazatchkine MD. Efficacy and Safety of Desensitization to Trimethoprim-Sulfamethoxazole in Human Immunodeficiency Virus-Infected Patients. The Journal of Infectious Disease 1995;172:611.
5. COTOX 2005 Waugh W. An open, randomised trial to compare desensitisation with rechallenge when restarting co-trimoxazole as prophylaxis against Pneumocystis carinii pneumonia (PCP) in patients with Human Immunodeficiency Virus (HIV) infection and a history of mild to moderate cutaneous and/or febrile reactions to co-trimoxazole (The COTOX trial). ISRCTN74775699.
6. Abouya 1992 Abouya YL, Beaumel A, Lucas S, Dago-Akribi A, Coulibaly G, N'Dhatz M, Konan JB, Yapi A, De Cock KM. Pneumocystis carinii pneumonia. An uncommon cause of death in African patients with acquired immunodeficiency syndrome. American review of respiratory disease 1992;145:617-20.
7. Absar 1994 Absar N, Daneshvar H, Beall G. Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients. Journal of allergy and clinical immunology 1994;93:1001-5.
8. Belchi 1996 Belchi-Hernandez J, Espinosa-Parra FJ. Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection. Annals of allergy, asthma & immunology 1996;76:355-8.
9. Benson 2004 Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. Morbidity and Mortality Weekly Report 2004;53:1-112.
10. Carr 1993 Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993;7:65-71.
11. Caumes 1997 Caumes E, Guermonprez G, Lecomte C, Katlama C, Bricaire F. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Archives of dermatology 1997;133:465-9.
12. Chintu 2004 Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Farrelly L, Kaganson N, Zumla A, Gillespie SH, Nunn AJ, Gibb DM, CHAP trial team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004;364:1865-71.
13. Fischl 1988 Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. Journal of the American Medical Association 1988;259:1185-9.
14. Freedberg 1998 Freedberg KA, Scharfstein JA, Seage GR 3rd, Losina E, Weinstein MC, Craven DE, Paltiel AD. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998;279:130-6.
15. Gilks 1990 Gilks CF, Ojoo SA, Ojoo JC, Brindle RJ, Paul J, Batchelor BI, Kimari JN, Newnham R, Bwayo J, Plummer FA, Warrell DA. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996;347:718-23.
16. Gluckstein 1995 Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprimsulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clinical infectious diseases 1995;20:849-53.
17. Goldie 2002 Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR 3rd, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Archives of Internal Medicine 2002;162:921-8.
18. Gompels 1999 Gompels MM, Simpson N, Snow M, Spickett G, Ong E. Desensitization to co-trimoxazole (trimethoprim-sulphamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction. Journal of infection 1999;38:111-5.
19. Gordin 1984 Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Annals of internal medicine 1984;100:495-499.
20. Grant 1997 Grant AD, Djomand G, Smets P, Kadio A, Coulibaly M, Kakou A, Maurice C, Whitaker JP, Sylla-Koko F, Bonard D, Wiktor SZ, Hayes RJ, De Cock KM, Greenberg AE. Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV-infected adults in Abidjan, Cote d'Ivoire. AIDS 1997;11:1357-64.
21. Grimwade 2003 Grimwade K, Swingler, G. Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. Cochrane Database of Systematic Reviews 2003, Issue CD003108.
22. Grimwade 2005 Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF. Effectiveness of cotrimoxazole prophylaxis onmortality in adults with tuberculosis in rural South Africa. AIDS 2005;19:163-8.
23. Hardy 1992 Hardy WD, Feinberg JD, Finkelstein M, Power ME, He W, Kaczka C, Frame PT, Holmes M, Waskin H, Fass RJ, Powderly WG, Steinbigel RT, Zuger A, Holzman RS. A controlled trial of trimethoprimsulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. New England journal of medicine 1992;327:1842-1848.
24. Hennessy 1995 Hennessy S, Strom BL, Berlin JA, Brennan PJ. Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis. Journal of General Internal Medicine 1995;10:380-6.
25. Hughes 1993 Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, Clumeck N, Masur H, Lancaster D, Chan C, Lavelle J, Rosenstock J, Falloon J, Feinberg J, LaFon S, Rogers M, Sattler F. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. New England journal of medicine 1993;328:1521-7.
26. Jaffe 1983 Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983;2(8359):1109- 1111.
27. Jick 1982 Jick H. Adverse reactions to trimethoprim- sulfamethoxazole in hospitalized patients. Reviews of infectious diseases 1982;4:426-28.
28. Joshi 2002 Joshi M, Chowdhary AS, Dalal PJ, Maniar JK. Parasitic diarrhoea in patients with AIDS. Natl Med J India 2002;15:72-4.
29. Kaplan 2000 Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clinical infectious diseases 2000;30:S5-14.
30. Kaplan 2002 Kaplan J, Masur H, Homes KK. Guidelines for the Preventing Opportunistic Infections Among HIV-Infected Persons. Morbidity and Mortality Weekly Report 2002;51:1-46.
31. Klatt 1994 Klatt EC, Nichols L, Noguchi TT. Evolving trends revealed by autopsies of patients with the acquired immunodeficiency syndrome. 565 autopsies in adults with the acquired immunodeficiency syndrome, Los Angeles, Calif, 1982-1993. Archives of pathology & laboratory medicine 1994;118:884-90.
32. Kovacs 1984 Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, Lane HC, Urmacher C, Honig C, Longo DL, Parker MM, Natanson C, Parrillo JE, Fauci AS, Pizzo PA, Masur H. Pneumocystis carinii pneumonia: A compar-ison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Annals of internal medicine 1984;100:663-671.
33. McNaghten 1999 McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 1999;13:1687-95.
34. Medina 1990 Medina I, Mills J, Leoung G, Hopewell PC, Lee B, Modin G, Benowitz N, Wofsy CB. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim- sulfamethoxazole versus trimethoprim-dapsone. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. New England journal of medicine 1990;323:776-82.
35. Mwaungulu 2004 Mwaungulu FB, Floyd S, Crampin AC, Kasimba S, Malema S, Kanyongoloka H, Harries AD, Glynn JR, Fine PE. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bulletin of the World Health Organization 2004;82:354-63.
36. Pakianathan 1999 Pakianathan MR, Kamarulzaman A, Ismail R, McMillan A, Scott GR. Hypersensitivity reactions to high-dose co-trimoxazole in HIV-infected Malaysian and Scottish patients. AIDS 1999;13:1787-8.
37. Phair 1990 Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. New England journal of medicine 1990;322:161-5.
38. Sattler 1988 Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Annals of internal medicine 1988;109:280-7.
39. Schneider 1992 Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, Nielsen TL, van der Graaf Y, Frissen JP, van der Ende IM, Kolsters AF, Borleffs JC. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. New England journal of medicine 1992;327:1836-41.
40. Shafer 1989 Shafer RW, Seitzman PA, Tapper ML. Successful prophylaxis of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in AIDS patients with previous allergic reactions. Journal of acquired immune deficiency syndromes 1989;2:389-93.
41. Small 1985 Small CB, Harris CA, Friedland GH, Klein RS. The treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Archives of internal medicine 1985;145:837-840.
42. UNAIDS 2004 Joint United Nations Programme on HIV/AIDS. UNAIDS 2004 Report on the global AIDS epidemic. UNAIDS 2004 Report on the global AIDS epidemic. Geneva, Switzerland. UNAIDS, 2004.
43. Wannamethee 1998 Wannamethee SG, Sirivichayakul S, Phillips AN, Ubolyam S, Ruxrungtham K, Hanvanich M, Phanuphak P. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand. International journal of epidemiology 1998;27:289-95.
44. Wharton 1986 Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld W, Hadley WK, Ingram-Drake L, Volberding PA, Hopewell PC. Trimethoprim- sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Annals of internal medicine 1986;105:37-44.
45. WHO 2006 World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. Geneva, Switzerland. WHO, 2006.
46. Wiktor 1999 Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, Djomand G, Ackah A, Domoua K, Kadio A, Yapi A, Combe P, Tossou O, Roels TH, Lackritz EM, Coulibaly D, De Cock KM, Coulibaly IM, Greenberg AE. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999;353:1469-75.